Epidemiology and costs of herpes zoster: Background data to estimate the impact of vaccination

Vaccine

Volumn 25, Issue 43, 2007, Pages 7598-7604

  Di Legami, Valeria ^a   Gianino, Maria Michela ^a   Atti, Marta Ciofi Degli ^b   Massari, Marco ^b   Migliardi, Alessandro ^c   Tomba, Gianpaolo Scalia ^d   Zotti, Carla ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c DoRS Centro di Documentazione per la Promozione della Salute Regione Piemonte   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Costs; General practitioners; Herpes zoster; Hospital admissions; Incidence; Treatments

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CHICKENPOX VACCINE; FAMCICLOVIR; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; RIFAMPICIN; VALACICLOVIR; VITAMIN B GROUP;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; GENERAL PRACTITIONER; HERPES ZOSTER; HOME CARE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; ITALY; MALE; MATHEMATICAL MODEL; MEDICAL RECORD REVIEW; MORBIDITY; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VACCINATION;

ADOLESCENT; ADULT; AGED; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; ITALY; MASS IMMUNIZATION; MIDDLE AGED; VACCINATION;

EID: 34848916675     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.049     Document Type: Article

References (35)

1. Hope-Simpson R.E. The nature of herpes zoster: a long term study and a new hypothesis. Proc R Soc Med 58 (1965) 9-20
2. Ragozzino M.W., Melton L.J., Kurland L.T., Chu C.P., and Perry O.H. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 61 5 (1982) 310-316
3. Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 127 (2001) 305-314
4. Thomas S.L., and Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 4 (2004) 26-33
5. Volpi A., Gross G., Hercogova J., and Johnson R.W. Current management of herpes zoster. The European view. Am J Clin Dermatol 6 5 (2005) 317-325
6. Di Luzio Paparatti U., Arpinelli F., and Visonà G. Herpes zoster and its complications in Italy: an observational survey. J Infect 38 2 (1999) 116-120
7. Brisson M., Gay N.J., Edmunds W.J., and Andrews N.J. Exposure to varicella boosts immunity to herpes-zoster: implication for mass vaccination against chickenpox. Vaccine 19-20 (2002) 2500-2507
8. Goldman G.S. Cost benefit analysis of universal varicella vaccination in the US: taking into account the closely related herpes-zoster epidemiology. Vaccine 23 (2005) 3349-3355
9. Edmunds W.J., Brisson M., and Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19 23-24 (2001) 3076-3090
10. Brisson M., Edmunds W.J., and Gay N.J. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 70 1 (2003) S31-S37
11. Chapman R.S., Cross K.R., and Fleming D.M. The incidence of shingles and its implication for vaccination policy. Vaccine 21 (2003) 2541-2547
12. Jumaan A.O., Yu O., Jackson L.A., Bohlke K., Galil K., and Seward J.F. Incidence of herpes zoster, before and after varicella-vaccination-associated decrease in the incidence of varicella, 1992-2002. JID 191 (2005) 2002-2007
13. Yih W.K., Brooks D.R., Lett S.M., Jumaan A.O., Zhang Z., Clements K.M., et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1988-2003. BMC Public Health 5 (2005) 68-77
14. Goldman S. Varicella susceptibility and incidence of herpes zoster among children and adolescents in a community under active surveillance. Vaccine 21 (2003) 4238-4242
15. Wagenpfeil S., Neiss A., and Wutzler P. Effects on varicella vaccination on herpes zoster incidence. Clin Microbiol Infect 10 (2004) 954-960
16. Scott F.T., Johnson R.W., Leedham-Green M., Davies E., Edmunds W.J., and Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 24 (2006) 1308-1314
17. http://www.ministerosalute.it/medicinali/bancadati/presentazione.jsp [last access: October 2006].
18. D.G.R. Region of Piemonte n. 73-13176 del 26/7/2004.
19. AIFA, 2004 (Revisione note CUF) n. 84: http://www.agenziafarmaco.it/aifa/servlet/wscs_render_attachment_by_id/111.102863.1144148103851.doc?id=111.3503.1139409015571 [last access: October 2006].
20. Lucioni C., and Ciriminna S. Il costo sociale del morbillo in età pediatrica. L'epidemia a Palermo nel 1996-97. Pharmacoeconomics Ital Res Articles 1 1 (1999) 17-33
21. D.G.R. Region of Piemonte n. 28-8148 del 30/12/2002.
22. Donhaue J.G., Choo P.W., Manson J.E., and Platt R. The incidence of herpes zoster. Arch Intern Med 155 (1995) 1605-1609
23. Ross C.A., Brown W.K., Clarke A., Caldwell W.F., Gordon E.R., Harvey J., et al. Herpes zoster in general practice. J R Coll Gen Pract 25 (1975) 29-32
24. Wilson J.B. Thirty one years of herpes zoster in a rural practice. BMJ 293 (1986) 1349-1351
25. Helgason S., Sigur J.A., and Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 2 (1996) 12-16
26. Paul E., and Thiel T. Epidemiology of varicella-zoster infections. Results of a perspective study in Ansbach, Germany. Hautarzt 47 (1996) 604-609
27. Czernichow S., Dupuy A., Flahault A., and Chosidow O. Herpes zoster: incidence study among sentinel general pratictioners. Ann Dermatol Venereol 128 (2001) 497-501
28. Chidiac C., Bruxelle J., Daures J.-P., Hoang-Xuan T., Morel P., Leplege A., et al. Characteristics of patient with herpes zoster on presentation to practictioners in France. Clin Infect Dis 33 (2001) 62-69
29. Brisson M., and Edmunds W.J. Epidemiology of varicella zoster virus in England and Wales. Med Virol 70 (2003) S9-S14
30. Opstelten W., van Essen G.A., Moons K.G.M., van Wijck A.J., Schellevis F.G., Kalkman C.J., et al. Do herpes zoster patient receive antivirals? A Dutch national survey in general practice. Fam Pract 22 (2005) 523-528
31. Lin F., and Hadler J.L. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 181 (2000) 1897-1905
32. Thomas S.L., Wheeler J.G., and Hall A.J. Case-control study of the effect of mechanical trauma on the risk of herpes zoster. BMJ 328 (2004) 439
33. Hope-Simpson R.E. Postherpetic neuralgia. J R Coll Gen Pract 25 157 (1975) 517-575
34. Gross G., Schofer H., Wassilew S., Friese K., Timm A., Guthoff R., et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 26 (2003) 277-289
35. Nowgesic E., Skowronski D., King A., and Hockin J. Direct costs attributed to chickenpox and herpes zoster in British Columbia: 1992-1996. CCDR 25 11 (1999) 100-104